Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Flora Peyvandi

Showing results (151-160 of 609) with videos related to

Pageof 61
Sort By:
Internal and Emergency Medicine|May 23, 2024
A case of lymphadenopathies with concomitant multiple acquired hemostasis disorders in an adult female patientAddolorata Truma, Andrea Artoni, Juri Alessandro Giannotta, et al.
Journal of Thrombosis and Thrombolysis|March 28, 2012
Case report: use of thienopyridines in a patient with acquired idiopathic thrombotic thrombocytopenic purpuraLuca A Lotta, Ilaria Mancini, Giacomo Tuana, et al.
Blood Cells, Molecules & Diseases|September 18, 2012
Drop of residual plasmatic activity of ADAMTS13 to undetectable levels during acute disease in a patient with adult-onset congenital thrombotic thrombocytopenic purpuraLuca A Lotta, Haifeng M Wu, Andrea Cairo, et al.
Haematologica|October 15, 2020
Dramatic presentation of acquired thombotic thrombocytopenic purpura associated with COVID-19Marco Capecchi, Cristina Mocellin, Chiara Abbruzzese, et al.
Haematologica|April 12, 2003
Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease)Pier Mannuccio Mannucci, Mehran Karimi, Ahmad Mosalaei, et al.
Thrombosis Research|May 27, 2015
Molecular characterization of 7 patients affected by dys- or hypo-dysfibrinogenemia: Identification of a novel mutation in the fibrinogen Bbeta chain causing a gain of glycosylationRosanna Asselta, Michela Robusto, Manuela Platé, et al.
Clinical Pharmacology and Therapeutics|March 6, 2004
CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapyFlora Peyvandi, Marta Spreafico, Simona Maria Siboni, et al.
Thrombosis Research|April 22, 2015
How the direct oral anticoagulant apixaban affects thrombin generation parametersArmando Tripodi, Lidia Padovan, Chantarangkul Veena, et al.
Journal of Clinical Medicine Research|November 10, 2025
A Challenging Case of Immune-Related Organizing Pneumonitis Following Programmed Cell Death 1 Inhibitor Therapy in Non-Small Cell Lung CancerGiovanni Paolozzi, Roberta Gualtierotti, Raffaella Rossio, et al.
Journal of Thrombosis and Haemostasis : JTH|June 12, 2025
The genetic spectrum of rare bleeding disordersSamin Mohsenian, Omid Seidizadeh, Andrea Cairo, et al.
Pageof 61

Showing results (151-160 of 609) with videos related to

Sort By:
Pageof 61
Internal and Emergency Medicine|May 23, 2024
A case of lymphadenopathies with concomitant multiple acquired hemostasis disorders in an adult female patientAddolorata Truma, Andrea Artoni, Juri Alessandro Giannotta, et al.
Journal of Thrombosis and Thrombolysis|March 28, 2012
Case report: use of thienopyridines in a patient with acquired idiopathic thrombotic thrombocytopenic purpuraLuca A Lotta, Ilaria Mancini, Giacomo Tuana, et al.
Blood Cells, Molecules & Diseases|September 18, 2012
Drop of residual plasmatic activity of ADAMTS13 to undetectable levels during acute disease in a patient with adult-onset congenital thrombotic thrombocytopenic purpuraLuca A Lotta, Haifeng M Wu, Andrea Cairo, et al.
Haematologica|October 15, 2020
Dramatic presentation of acquired thombotic thrombocytopenic purpura associated with COVID-19Marco Capecchi, Cristina Mocellin, Chiara Abbruzzese, et al.
Haematologica|April 12, 2003
Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease)Pier Mannuccio Mannucci, Mehran Karimi, Ahmad Mosalaei, et al.
Thrombosis Research|May 27, 2015
Molecular characterization of 7 patients affected by dys- or hypo-dysfibrinogenemia: Identification of a novel mutation in the fibrinogen Bbeta chain causing a gain of glycosylationRosanna Asselta, Michela Robusto, Manuela Platé, et al.
Clinical Pharmacology and Therapeutics|March 6, 2004
CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapyFlora Peyvandi, Marta Spreafico, Simona Maria Siboni, et al.
Thrombosis Research|April 22, 2015
How the direct oral anticoagulant apixaban affects thrombin generation parametersArmando Tripodi, Lidia Padovan, Chantarangkul Veena, et al.
Journal of Clinical Medicine Research|November 10, 2025
A Challenging Case of Immune-Related Organizing Pneumonitis Following Programmed Cell Death 1 Inhibitor Therapy in Non-Small Cell Lung CancerGiovanni Paolozzi, Roberta Gualtierotti, Raffaella Rossio, et al.
Journal of Thrombosis and Haemostasis : JTH|June 12, 2025
The genetic spectrum of rare bleeding disordersSamin Mohsenian, Omid Seidizadeh, Andrea Cairo, et al.
Pageof 61